

## SUPPLEMENTARY MATERIALS

### Supplementary methods ..... 2

- Ethics statement
- Animals
- Induction of postnatal recombination and monitoring of mice
- Mouse Tissue processing and histopathological analysis
- Transmission electron microscopy (TEM)
- Samples from Crohn's disease patients
- Staining procedures
- *In situ* hybridization
- Quantification of Lysozyme and *Lgr5* positive cells
- Quantification of *Olfm4* and *HopX* expression
- Quantification of Hsp60 expression
- Isolation of primary IECs
- Primary crypt isolation and intestinal organoid culture
- Measurement of living cells and cellular ATP content
- mRNA isolation and quantitative real-time PCR
- Statistical analysis

### Supplementary figures ..... 9

- Fig. S1. Inflammation but not genotype causes alterations in the ISC niche in TNF<sup>ΔARE</sup> mice
- Fig. S2. Risk of recurrence increases with the cumulative number of risk factors in CD patients
- Fig. S3. Smoking and genetic risk factors have no additional impact on ISC niche risk factors
- Fig. S4. Paneth cell phenotype and *LGR5* expression pattern are not predictive for disease recurrence in inflamed CD patients
- Fig. S5. Induction of autophagy in mouse models of inflammation and mitochondrial dysfunction
- Fig. S6. Loss of Hsp60 in intestinal stem cells induces apoptosis subsequently to loss of *Lgr5*-positive cells
- Fig. S7. Hsp60 negative cells do not proliferate and remain in the crypt base, but crypts remain *Olfm4* and *Hopx* positive
- Fig. S8. Hsp60 negative cells do not give rise to goblet cells, enteroendocrine cells or tuft cells
- Fig. S9. Wnt factor supplementation does not rescue growth of organoids derived from inflamed TNF<sup>ΔARE</sup> mice
- Fig. S10. DCA treatment of WT ileal organoids

### Supplementary tables ..... 25

- Table S1. Patients' characteristics at time of surgery.
- Table S2. Primary antibodies used in the study.
- Table S3. Secondary antibodies used in the study
- Table S4. Primer sequences and probes

### References ..... 28

## Supplementary methods

### **Ethics statement**

The maintenance and breeding of mouse lines and all experiments were approved by the Committee on Animal Health and Care of the local government body of the state of Upper Bavaria (Regierung von Oberbayern; TVA 55.2-1-54-2532-214-2013 and TVA 55.2-1-54-2532-217-2014) and performed in strict compliance with the EEC recommendations for the care and use of Lab. Anim. (European Communities Council Directive of 24 November 1986 (86/609/EEC)). The use of surgically resected CD patient samples was approved by AFFSAPS (IDRCB: 2009-A00205-52), the French Ethic Committee- Hôpital Saint-Louis (CPP 2009/17) and declared to clinicaltrials.gov (NCT03458195). All patients provided an informed written consent. For generation of human organoids, the use of surgically resected human tissue samples was approved by the Ethics Committee of the Medical Faculty of TUM and obtained after prior informed written consent.

### **Animals**

*Hsp60<sup>flox/flox</sup>* mice and *Hsp60<sup>flox/flox</sup> × Lgr5CreER<sup>T2</sup>-IRES-Egfp<sup>Tg</sup>* mice (to generate ISC-specific *Hsp60* knockout mice via tamoxifen-induction (*Hsp60<sup>Δ/ΔISC</sup>* mice) were generated as described previously [1]. *TNF<sup>ΔARE</sup>* mice were initially provided from Case Western University, Cleveland. All mice were housed (12h light/ dark cycles, 24-26°C) under SPF conditions and bred for several generations in the animal facility to harmonize the intestinal microbiota. Mice received a standard diet (autoclaved V1124-300; Ssniff, Soest, Germany) and autoclaved water *ad libitum*. Animals were killed by CO<sub>2</sub> inhalation. *TNF<sup>ΔARE</sup>* mice and WT littermates were sacrificed at 18 weeks of age.

### **Induction of postnatal recombination and monitoring of mice**

Phytoestrogen free pellets (ssniff, Soest, Germany) were fed for 4 weeks to male 6 weeks old *Hsp60<sup>flox/flox</sup> × Lgr5CreER<sup>T2</sup> Egfp<sup>Tg</sup>* and their appropriate control mice, respectively. Afterwards, they received 400 mg tamoxifen citrate (Tam) per kg chow feed (LASvendi, Soest, Germany) in pellets *ad libitum* for 7 days. Body weight was monitored before, during and after oral administration of tamoxifen. Body weight, general condition, behavior and intestinal symptoms were assessed by a score

between 0 and 10 each according to the approved application for animal experiments. Animals were sacrificed at the indicated time points.

### ***Mouse Tissue processing and histopathological analysis***

The intestine was removed immediately after killing, trimmed free of adjacent tissue and cleaned of stool. Small intestinal tissues were either immediately fixed for preparation of cross sections or cut open and prepared as a 'swiss role'. Tissues were fixed in 4% PBS buffered formaldehyde, dehydrated and embedded in paraffin (FFPE). For histopathological assessment, 5 µm sections were stained with hematoxylin (of Mayer) and 0.2% eosin (ethanolic solution; both Medite, Burgdorf, Germany) in an automated staining machine (Leica, Soest, Germany). Ileal sections were blindly assessed for mononuclear cell infiltration into lamina propria, crypt hyperplasia, goblet cell depletion and ulcer formation resulting in a score from 0 (not inflamed) to 12 (highly inflamed) as described previously [4].

### ***Transmission electron microscopy (TEM)***

For TEM analysis, longitudinal sections of freshly dissected ileum samples were fixed in 2.5% electron microscopy grade glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4 (Science Services, Munich, Germany), postfixated in 2% aqueous osmium tetroxide (Dalton, 1955), dehydrated in gradual ethanol (30–100%) and propylene oxide, embedded in Epon (Merck, Darmstadt, Germany) and cured for 24 hours at 60°C. Semithin sections were cut and stained with toluidine blue. Ultrathin sections of 50 nm were mounted on 200 mesh copper grids, contrasted with uranyl acetate and lead citrate before examination by transmission electron microscopy (Zeiss Libra 120 Plus, Carl Zeiss NTS GmbH, Oberkochen, Germany). Pictures were acquired at 1260–12500x magnification, using a Slow Scan CCD-camera and iTEM software (Olympus Soft Imaging Solutions, Münster, Germany).

### ***Samples from Crohn's disease patients***

CD patients' tissue samples were collected during a prospective multicenter study performed by the REMIND group published previously [5]. From this cohort, 70 patients with a paraffin-embedded ileal margin sample available for histological analysis were selected [6]. Patients' characteristics at time of surgery are given in **Supplementary table 1**. Briefly, to assess inflammation at time of surgery, full-thickness 3-µm sections

of paraffin-embedded ileal margin were stained with hematein eosin saffron (HES). Each section was jointly analyzed by two expert pathologists blinded to the baseline detailed clinical data and to the post-operative outcomes of the patients. The ileal margin was considered as inflamed if (i) mucosal erosion or ulceration or (ii) cryptic abscess/cryptitis was noticed. Ileocolonoscopy was performed 6 -12 months after surgery. The physician performing the endoscopy evaluated the Rutgeerts score. Two physicians checked the colonoscopy's report blinded to histological analysis and post-operative treatment. Endoscopic recurrence was defined as a Rutgeerts score  $\geq$  i2.

### **Staining procedures**

Immunohistochemical (IHC) and immunofluorescence (IF) stainings were performed on 4  $\mu$ m FFPE tissue sections as described previously [1]. To stain intestinal organoids, Matrigel containing organoids was gently dissolved in cold PBS (Sigma-Aldrich, Taufkirchen, Germany), centrifuged for 5 min at 300 g, and pelleted organoids were carefully fixed in 4% formaldehyde. The suspension was transferred to a microscope glass slide, incubated for 15 min at room temperature and washed subsequently before starting the described [1] staining procedure by adding blocking buffer. Antibodies and dilutions are given in **Supplementary Table 2 and 3**. For detection of apoptosis in FFPE tissue sections (TUNEL-assay) the Apo-BrdU *In Situ* Fragmentation Assay Kit (BioVision, Milpitas, CA) was used according to the manufacturer's instructions. Tissue sections treated with DNaseI (Macherey-Nagel, Düren, Germany) for 15 min immediately after antigen retrieval served as positive controls for the TUNEL assay, murine intestinal segments incubated *ex vivo* in 1  $\mu$ M staurosporine for 2 h at 37 °C before embedding served as positive controls for CC3 staining. For IF, stainings were visualized using the Flouview FV10i microscope (Olympus, Shinjuku, Japan). For IHC co-staining, sections were incubated for 20 min with 3% H<sub>2</sub>O<sub>2</sub> (Sigma- Aldrich, Taufkirchen, Germany) after the first antigen detection using the DAB enhanced liquid substrate system (Sigma-Aldrich). Subsequently, sections were blocked and a second antibody was applied as described above. To detect the second antigen, the HRP green solution set (42 Life sciences GmbH, Bremerhaven, Germany) was used. IHC stainings were scanned and further analyzed using a PreciPoint M8 microscope (Precipoint, Freising, Germany).

### ***In situ* hybridization**

*In situ* hybridization for murine *Lgr5*, human *LGR5* and *Olfm4* was performed on 5µm thick tissue sections using the RNAscope-2.5 HD *in situ* assay kit-Brown (ACD, Bio-Techne GmbH, Wiesbaden, Germany) according the manufacturer's instructions. Probes were :RNAscope Probe-Mm-Lgr5; RNAscope Probe-Mm-*Olfm4*; RNAscope Probe-Mm-*Hopx*, and RNAscope Probe-Hs-*LGR5*, all from ACD. Sections were counterstained with hematoxylin, dipped in 0.02% ammonium hydroxide solution and were mounted with xylene based mounting medium. For IHC co-staining, tissue sections were incubated with 3% H<sub>2</sub>O<sub>2</sub> (Sigma-Aldrich) for 20 min after conducting *in situ* hybridization stained as described above. For detection of IHC-stained antigens the HRP green solution set (42 Life sciences GmbH, Bremerhaven, Germany) was used. Sections were counterstained with hematoxylin and mounted with xylene based mounting medium. Stained slides were scanned and further analyzed via the PreciPoint M8 microscope.

### ***Quantification of Lysozyme and Lgr5 positive cells***

Numbers of Lysozyme (Lyz/LYZ) positive and *Lgr5/LGR5* positive cells were determined in ileal tissue sections stained for Lyz/LYZ by IF and for *Lgr5/LGR5* by *in situ* hybridization. A total number of 80 (for human) or 50 (for mice) well oriented crypts were quantified. Signals arising from cells below the +7 position (<+7) were considered to be located in lower crypt, upper crypt was defined as >+7 (**Supplemental Fig.4A**). To assess *Lgr5/LGR5* expression, dots representing *Lgr5/LGR5* transcripts were counted and crypts containing ≥15 transcripts (for human) and ≥10 transcripts (for mice), respectively, were considered as crypts with high *Lgr5* expression. To assess the granularity of Lyz/LYZ positive cells, a minimum of 150 PCs (ranges between 150 and 334 PCs) were quantified in human tissue sections, for mice all PCs contained in 50 crypts were analyzed. Lyz/LYZ positive cells were considered as highly granular if ≥2 Lyz/LYZ positive granules were visible within the cell. The quantification was performed in a blinded manner.

### ***Quantification of Olfm4 and HopX expression***

Quantification of *Olfm4* and *Hopx* expression was performed in small intestinal tissue sections stained by *in situ* hybridization. For TNF<sup>ΔARE</sup> mice, a total number of 50 well oriented ileal crypts were quantified. Total numbers of *Olfm4* positive cells were

determined in the crypt base (<+7 cells, Supplemental Fig. 4A). For *Hsp60*<sup>ΔISC</sup> mice, images of *Hopx* *in situ* hybridization stainings were analyzed using the ImageJ software. In at least 30 open, well-oriented crypts total crypt IEC area up to the crypt-villus junction was defined and within this area, the area positive for the respective staining was determined. For *Olfm4*, owing to the discontinuous expression pattern of this marker gene, the distance of the most upper *Olfm4* positive cell to the crypt ground (position 0) was measured and normalized to crypt length. All quantifications were performed in a blinded manner.

### **Quantification of Hsp60 expression**

Volocity 2D-3D imaging software was used for the quantification of fluorescence intensity in IF stained tissue section. Quantification of the Hsp60 signals was performed in a minimum of 30 well oriented intestinal crypts. The crypt base area was selected according to **Supplemental Fig. 4A** (<+7 cells) and the positive signal was quantified based on the best fitting threshold, covering positive areas of the crypt base. The same threshold was used for quantification of all sections.

### **Isolation of primary IECs**

Primary IEC were purified as previously described [1]. Approximately 6 cm of intestine were inverted on a needle, vortexed vigorously and incubated (37 °C, 15 min) in DMEM containing 10% fetal calf serum (FCS superior, Biochrom, Berlin), 1.0% Glutamine, 0.8% antibiotics/antimycotics (all Sigma-Aldrich, St Louis, MO) supplemented with 1 mM dithiothreitol (Roth, Karlsruhe, Germany). The IEC suspensions were centrifuged (7 min, 300g, RT) and cell pellets were re-suspended in DMEM containing fetal calf serum, L-glutamine and antibiotics. The remaining tissue was incubated in 20 ml PBS (10 min, 37 °C) containing 1.5 mM EDTA (Roth). Thereafter, the tissue was discarded and the cell suspension from this step was centrifuged as mentioned above. Finally, primary IEC were purified by centrifugation through a 20%/40% discontinuous Percoll gradient (GE Healthcare, Uppsala, Sweden) at 600g for 30 min.

### **Primary crypt isolation and intestinal organoid culture**

Primary small intestinal crypts from mouse (ileum, jejunum) and human (ileum) were isolated by tissue incubation in 2mM EDTA (Fisher, Dreieich, Germany) and cultured as described elsewhere [1, 7]. Briefly, crypts were embedded in 25µl matrigel (BD

Biosciences, Franklin Lakes, NJ) and cultured in 48 well plates. Until otherwise indicated, murine organoids were grown in crypt culture medium (CCM), advanced DMEM/F12 medium (Gibbco, Cincinnati, OH) containing 2 mM GlutaMax (Gibbco), 10 mM HEPES, penicillin, streptomycin and amphotericin (all Sigma- Aldrich, Taufkirchen, Germany) supplemented with N2, B27 (both Gibbco), 1 mM N-acetylcystein (Sigma- Aldrich), 50 ng ml<sup>-1</sup> EGF (ImmunoTools, Friesoythe, Germany), 100 ng ml<sup>-1</sup> noggin and 0.5 µg ml<sup>-1</sup> R-spondin 1 (both PeproTec, Rocky Hill, NJ). Medium containing Wnt factors suitable for murine organoids (Intesticult) was obtained from STEMCELL Technologies, Grenoble, France. Human organoids were kindly provided by Tamara Zietek and maintained in Human Intesticult medium (STEMCELL Technologies, Grenoble, France). Two days prior to the start of experiments, medium of human organoids was changed to CCM. To assess seeding efficiency, total numbers of propagating organoids were counted at day 1 after seeding (baseline) and numbers of viable organoids were subsequently determined at the indicated time points in the same cell culture plate wells. Data are presented as proportion of living organoids over baseline counts. For quantification of *de novo* crypt formation (budding), organoids were classified according to number of visible bud structures (0, 1, 2, 3, >4). A minimum of 80 organoids (ranging between 80-140) was included in the analyses. *Ex vivo* induction of the *Hsp60* knockout was achieved by adding 1.5 µl of 100 µM (Z)-4-hydroxytamoxifen (4-OHT; LKT, St Paul, MN) to 300 µl CCM per well of a 48 well plate. When indicated, 2.5µM oligomycin (Sigma- Aldrich, Taufkirchen, Germany) or 15mM DCA (Sigma- Aldrich, Taufkirchen, Germany) were added to the culture medium for 24h. Growth measurements were performed using an Olympus CK X 41 microscope and Olympus cellSens Entry software.

### **Measurement of living cells and cellular ATP content**

Life- and dead- cell protease activity was measured using the MultiTox-Fluor Cytotoxicity Assay and ATP content was measured using the CellTiter-Glo Luminescent Cell Viability Assay (both from Promega, Mannheim, Germany), according to the manufacturer's instructions in a 96-well format. Fluorescence and luminescence were measured using the Tecan infinite M200 (Tecan Group Ltd., Männedorf, Switzerland) and the i-control™ Microplate Reader software (Tecan, Grödig, Austria).



***mRNA isolation and quantitative real-time PCR***


RNA of a total ileal tissue, ileal IECs, primary crypts and small intestinal organoids was isolated using the NucleoSpin RNAII kit (Macherey-Nagel, Düren, Germany) according to the manufacturer's instructions. Quantitative Real-time PCR (qRT-PCR) was performed using 1 µl cDNA in a Light Cycler 480 system (Roche Diagnostics, Mannheim, Germany) applying the Universal Probe Library system according to the manufacturer's instructions. Primer sequences and probes are given in **Supplementary table 4**. Relative induction of gene mRNA expression was calculated based on Ct values using the expression of *Hprt* for normalization. Data were expressed as fold change over controls.

***Statistical analysis***

Data of 3–6 animals per experimental group are indicated. Statistical computations were performed using GraphPad Prism (GraphPad, La Jolla, CA). Statistical test used were: unpaired t-test for two group-comparisons or One-Way analysis of variances followed by Tukey test for comparisons comprising more than two groups. To determine statistically significant differences in *de novo* crypt formation, a Kruskal–Wallis test on ranks followed by Dunn's test was performed. Correlation analyses were performed according to Pearson test. Fisher-Exact test and Chi-Square test were performed to determine differences in the probability of recurrence of CD patients. Data are presented as mean ± standard error mean. and P-values below 0.05 were considered as statistically significant. Differences reached statistical significance with P values <0.05 (\*), <0.01 (\*\*) and P<0.001 (\*\*\*).




Supplementary figures




**Supplementary figure 1: Inflammation but not genotype causes alterations in the ISC niche in TNF<sup>ΔARE</sup> mice**

(A, B) Ileal tissue sections from non-inflamed TNF<sup>ΔARE</sup> and WT mice were analyzed. (A) Quantification of the total number of Lysozyme positive (Lyz<sup>+</sup>) cells (left) and the proportion of highly granular Lyz<sup>+</sup> cells (≥2 granules). (B) Representative pictures of IF co-staining of Lysozyme (red) and E-cadherin (IEC borders, grey) counterstained with Dapi (nuclei, blue), including magnification showing Lyz<sup>+</sup> granules. (C, D) Ileal tissue sections from TNF<sup>ΔARE</sup> mice with different levels of inflammation were analyzed. (C) Representative pictures of *Lgr5 in situ* hybridization and IHC co-staining for E-cadherin. Numbers above indicate the respective histopathological score (HS). (D) Quantification of the number of *Lgr5*<sup>+</sup> cells per crypt. (E, F) Ileal tissue sections from non-inflamed TNF<sup>ΔARE</sup> and WT mice were analyzed. (E) Quantification of the number of crypts (left) and of *Lgr5 in situ* hybridization giving the proportion of crypts with high *Lgr5* expression (≥10 *Lgr5* transcripts). (F) Representative pictures of *Lgr5 in situ* hybridization in WT mice, including magnification. (G, H) Ileal tissue sections from TNF<sup>ΔARE</sup> mice with different levels of inflammation were analyzed. (G) Representative pictures of *Olfm4 in situ* hybridization, including magnifications; numbers indicate the respective histopathological score (HS). (H) Correlation analysis (Pearson) of the number of *Olfm4*<sup>+</sup> cells and HS. (I) qRT-PCR analysis of TNF<sup>ΔARE</sup> and WT mice-derived IECs for *Olfm4* (N=5). Statistics were performed by unpaired *t*-test. Bars represent mean+s.e.m. Asterisks indicate significant differences \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001.



**Supplementary figure 2: Risk of recurrence increases with the cumulative number of risk factors in CD patients non-inflamed at time of surgery**

Ileal tissue sections classified as non-inflamed at time of surgery of CD patients undergoing resection surgery were analyzed. Tissue sections were stained for Lysozyme (LYZ) by IF and total number of LYZ positive cells in crypts were determined. CD patients with endoscopic recurrence (Rutgeerts score  $\geq 2$ ) 6-12 months after surgery were compared to CD patients not experiencing recurrence. **(A)** overall comparison of recurrent versus non-recurrent patients for the total number of LYZ<sup>+</sup> cells. Statistics were performed by unpaired *t*-test. Bars represent mean+s.e.m. **(B)** From left to right: distribution of the total number of LYZ<sup>+</sup> cells among recurrent (red circles) and non-recurrent (black circles) CD patients with median indicated; probability of CD patients to experience recurrence if above or below the median for the respective marker; representative pictures showing sections from CD patients above or below median, IF co-staining of Lysozyme (red) and E-cadherin (IEC borders, grey) counterstained with Dapi (nuclei, blue). Chi-square test was used to determine significance. **(C)** Total numbers of highly granular PCs (below median), PCs in upper crypt (above median), highly *Lgr5* expressing crypts (below median) and *Lgr5* expression in upper crypts (above median) were assigned as risk factors resulting in a possible score from 0-4 for recurrent CD patients. The probability of CD patients non-inflamed at time of surgery to experience recurrence with indicated numbers of risk factors is shown. Statistical analyses were performed via Fisher-Exact test. Differences were considered statistically significant for *P*<0.05.




### Supplementary figure 3: Smoking and genetic risk factors have no additional impact on ISC niche risk factors

Data from ileal tissue sections of CD patients undergoing resection surgery were analyzed for the smoking status of CD patients. (A) Overview of CD patient numbers and smoking status for baseline and endoscopic follow-up disease classification. (B, C) Total numbers of LYZ<sup>+</sup> cells, numbers of highly granular LYZ<sup>+</sup> cells ( $\geq 2$  granules), numbers of LYZ<sup>+</sup> cells in upper crypt, proportion of crypts with high *LGR5* expression ( $\geq 15$  *LGR5* transcripts), and proportion of crypts with *LGR5* expression in upper crypt are depict for all patients regardless endoscopic follow-up disease classification according to the smoking. (D, E) The same readouts as in (B) and (C) are depict for patients experiencing endoscopic recurrence according to the smoking

status, showing no additional impact of smoking on the risk factors analyzed. **(F)** Distribution of CD-associated SNPs ATG16L1 rs6752107 and NOD2 rs2066845 or rs2066844 among recurrent and non-recurrent CD patients. **(G)** Numbers of risk alleles in recurrent and non-recurrent CD patients. **(H)** The same readouts as in **(B)** and **(C)** are depict according to patients' genetics. Dots representing patients experiencing recurrence are given in red. No differences were found between genotypes for the risk factors analyzed. Statistical analyses were performed via unpaired *t*-test. Bars represent mean+s.e.m. Asterisks indicate significant differences \**P*<0.05.


4



**Supplementary figure 4: Paneth cell phenotype and *LGR5* expression pattern are not predictive for disease recurrence in inflamed CD patients**

Ileal tissue sections classified as inflamed at time of surgery of CD patients undergoing resection surgery were analyzed. Tissue sections were stained for Lysozyme (LYZ) by IF and for *LGR5* by *in situ* hybridization, respectively, and expression patterns were quantified. From top to bottom: total numbers of LYZ<sup>+</sup> cells, numbers of highly granular LYZ<sup>+</sup> cells (≥2 granules), numbers of LYZ<sup>+</sup> cells in upper crypt, proportion of crypts with high *LGR5* expression (≥15 *LGR5* transcripts), and proportion of crypts with *LGR5* expression in upper crypt were determined. CD patients with endoscopic recurrence (Rutgeerts score ≥i2) 6-12 months after surgery were compared to CD patients not experiencing recurrence. From left to right: distribution of the respective marker among recurrent (red circles) and non-recurrent (black circles) CD patients with median indicated; probability of CD patients to experience recurrence if above or below the median for the respective marker; overall comparison of recurrent versus non-recurrent patients for the respective marker. Statistics were performed by unpaired *t*-test. Bars represent mean+s.e.m. Asterisks indicate significant differences \**P*<0.05.






**Supplementary figure 5: Induction of autophagy in mouse models of inflammation and mitochondrial dysfunction**


Representative pictures of IF co-staining of LC3 (red), Hsp60 (green) and E-cadherin (IEC borders, grey) counterstained with Dapi (nuclei, blue) and qRT-PCR analysis of LC3a mRNA levels. **(A)** Ileal tissue sections from TNF $\Delta$ ARE mice and WT littermates. Numbers above indicate the respective histopathological score (HS) **(B)** Primary isolated crypts from TNF $\Delta$ ARE mice and WT littermates (N=5). **(C)** Ileal tissue sections from Hsp60 $\Delta$ /ΔISC and Hsp60<sup>flox/flox</sup> mice at D2 and D4 after end of tamoxifen treatment. **(D)** IEC isolates from Hsp60 $\Delta$ /ΔISC and Hsp60<sup>flox/flox</sup> mice. Statistical analysis was performed via unpaired *t*-test or One-way analysis of variance (ANOVA) followed by Tukey test when comparing more than two groups. Bars represent mean+s.e.m. Asterisks indicate significant differences \**P*<0.05, \*\**P*<0.01.





**Supplementary figure. 6: Loss of Hsp60 in intestinal stem cells induces apoptosis subsequently to loss of *Lgr5*-positive cells**


Ileal tissue sections from Hsp60<sup>Δ/ΔISC</sup> mice and Hsp60<sup>fl<sup>ox</sup>/fl<sup>ox</sup></sup> controls were analyzed at different time points after end of tamoxifen treatment. (**A, B**) IF co-staining of eGFP (**A**, red, indicating *Lgr5* expressing cells) or lysozyme (Lyz) (**B**, red, indicating Paneth cells) and TUNEL staining (green, indicating apoptotic cells), for the indicated time-points, including magnifications. Lower panel: positive control for TUNEL assay (tissue sections treated with DNaseI), overlap of eGFP and TUNEL staining is indicated in yellow. (**C**) IF co-staining of cleaved caspase 3 (red, indicating apoptotic cells), Hsp60 (green) and E-cadherin (IEC borders, grey) counterstained with Dapi (nuclei, blue) in crypts; right side: magnifications including bright field images. Right panel: CC3 staining in villi, serving as a positive control.




**Supplementary figure 7: Hsp60 negative cells do not proliferate and remain in the crypt base, but crypts remain *Olfm4* and *Hopx* positive**


Small intestinal tissue sections from Hsp60<sup>Δ/ΔISC</sup> mice and Hsp60<sup>flox/flox</sup> controls were analyzed at different time points after end of tamoxifen treatment. (A) IF co-staining of Hsp60 (green), E-cadherin (IEC borders, grey) and Ki67 (proliferation, red) in ileal tissue sections. Dapi stains the nuclei in blue. (B, C) Left: representative pictures of *Olfm4* (B) and *Hopx* (C) *in situ* hybridization, including magnifications. (B) Right: quantification of the distance of the most upper *Olfm4* positive cell to the crypt ground normalized to crypt length (C) Right: quantification of the area positive for *Hopx* normalized to crypt area (N=3). Statistical analysis was performed via One-way analysis of variance (ANOVA) followed by Tukey test. Bars represent mean+s.e.m. Asterisks indicate significant differences \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001.












**Supplementary figure 8: Hsp60 negative cells do not give rise to goblet cells, enteroendocrine cells or tuft cells**

Ileal tissue sections from Hsp60<sup>Δ/ΔISC</sup> mice and Hsp60<sup>flox/flox</sup> controls were analyzed at different time points after end of tamoxifen treatment. IF co-staining of Hsp60 (green), E-cadherin (IEC borders, grey) and (A) Muc2 (goblet cells, red), (B) ChgA (enteroendocrine cells, red), (C) Dclk1 (tuft cells) (red). Dapi stains the nuclei in blue. Muc2, ChgA and Ccl1 positive cell remain Hsp60 positive throughout the experiment.




### Supplementary figure 9: Wnt factor supplementation does not rescue growth of organoids derived from inflamed TNF<sup>ΔARE</sup> mice

(A) Growth characteristics of ileal organoids derived from non-inflamed TNF<sup>ΔARE</sup> mice and WT littermates. Left: proportion of living organoids; right: quantification of *de novo* crypt formation (budding) at day 5 of *ex vivo* culture. (B) Ileal (left) and jejunal (right) crypts derived from non-inflamed and inflamed TNF<sup>ΔARE</sup> mice were cultured in commercially available medium containing Wnt factors (Intesticult) for 5 days. Proportion of living organoids and representative bright field pictures are shown. (C) Organoids derived Hsp60<sup>flox/flox</sup> mice were treated with tamoxifen to induce ISC-specific Hsp60 loss and sampled 2 days later. Tamoxifen treated Cre negative organoids served as control. Left: representative bright field pictures; Right: qRT-PCR analysis of *Lgr5* and genes involved in PC function (N=6). (D) Representative pictures of IF



co-staining for Lysozyme (red) and E-cadherin (IEC borders, grey) counterstained with Dapi (nuclei, blue), including bright field pictures. Dotted lines indicate cell borders of Lyz positive (Lyz<sup>+</sup>) cells; asterisks indicate Lyz<sup>+</sup> cells magnified in the pictures on the right side; Right: quantification of Lyz<sup>+</sup> cell numbers per crypt (upper graph) and the proportion of highly granular ( $\geq 2$  granules) Lyz<sup>+</sup> cells (lower graph). **(E)** Measurement of living cells in murine (WT, left) and human (right) organoid cultures after treatment with oligomycin for 24h (N $\geq 3$ ). Statistical analysis was performed via unpaired *t*-test. Bars represent mean+s.e.m. Asterisks indicate significant differences \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001.



**Supplementary figure 10: DCA treatment of WT ileal organoids**

Ileal organoids derived from WT mice were treated with DCA for 24h. **(A)** Left: bright field and IF co-staining of Lyz (red) and E-cadherin (IEC borders, grey) counterstained with Dapi (nuclei, blue). Dotted lines indicate cell borders of Lyz positive (Lyz<sup>+</sup>) cells; asterisks indicate Lyz<sup>+</sup> cells magnified in the pictures on the right side. **(B)** Quantification of Lyz<sup>+</sup> cell numbers per crypt (left graph) and the proportion of highly granular (≥2 granules) Lyz<sup>+</sup> cells (right graph). **(C)** qRT-PCR analysis of intestinal organoids for *Lgr5* and Paneth cell function-associated genes (upper panel) and for genes associated with mitochondrial signaling (lower panel, N=6). **(D)** Same analysis as in **(C)** for human organoids derived from the small intestine and treated with DCA for 24h (N=6). Statistical analysis was performed via unpaired *t*-test. Bars represent mean+s.e.m. Asterisks indicate significant differences \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001.

## Supplementary tables

Table S1. Patients' characteristics at time of surgery.

Total number of patients included		n=70
Men		28 (40%)
Median age (y, IQR)		31.7 (26.4-44.0)
Age at Crohn's Disease diagnosis (Montreal classification)		
- ≤16 years (A1)		5 (7%)
- 17 - 40 years (A2)		56 (80%)
- >40 years (A3)		9 (13%)
Median disease duration (y, IQR)		6.7 (1.8-12.5)
Median time between resection and colonoscopy (mo, IQR)		6.7 (6.1-8.4)
Smoking		
- Active smoker		23 (33%)
- Smoking cessation at surgery		6 (9%)
- Non-smoker		41 (58%)
Previous intestinal resection		13 (19%)
Number of previous resection(s)		
- 0		57 (82%)
- 1		7 (10%)
- 2		3 (4%)
- 3		3 (4%)
Surgical indication		
- Stricturing complication		47 (67%)
- Penetrating complication		22 (31%)
- Failure of drug therapy		1 (2%)
Anoperineal lesion		13 (19%)
Extra-digestive symptoms		
- Joint manifestations		18 (26%)
- Skin manifestations		6 (9%)
- Eye manifestations		2 (3%)
Previous exposure to anti-TNF therapy		42 (60%)
Anti-TNF therapy within 3 months before surgery		29 (41%)
Previous exposure to thiopurines		53 (76%)
Thiopurines within 3 months before surgery		20 (29%)
Ileal resection margin inflamed		20 (29%)

Table S2. Primary antibodies used in the study.

Primary antibodies:	Species:	Company:	Dilution:
Anti-CC3	Rabbit	Cell signaling Technology, Danvers, MA	1:100
Anti-E-cadherin	Mouse	Abcam, Cambridge, UK	1:300
Anti-GFP (XP)	Rabbit	Cell signaling Technology, Danvers, MA	1:200
Anti-HSP60	Goat	Santa Cruz Biotechnology, Santa Cruz, CA	1:200
Anti-Lysozyme	Rabbit	Dako, Agilent, Santa Clara	1:1000
Anti-Chromogranin A	Rabbit	Abcam, Cambridge, UK	1:100
Anti-Dclk1	Rabbit	Biomol, Hamburg, Germany	1:100
Anti-Ki67	Rabbit	Cell signaling Technology, Danvers, MA	1:400
Anti-MAP LC3 $\alpha/\beta$	Goat	Santa Cruz Biotechnology, Santa Cruz, CA	1:200
Anti-Muc2	Rabbit	BioTechne, Wiesbaden, Germany	1:200
Anti-PKR (M-515)	Rabbit	Santa Cruz Biotechnology, Santa Cruz, CA	1:100

Table S3. Secondary antibodies used in the study

Secondary antibodies:	Company:	Dilution:
HRP conjugated mouse anti goat IgG	Dianova, Hamburg, Germany	1:300
HRP conjugated donkey anti rabbit IgG	Dianova, Hamburg, Germany	1:300
Alexa Fluor donkey anti goat 488	Life Technologies, Carlsbad, CA	1:200
Alexa Fluor donkey anti rabbit 546	Life Technologies, Carlsbad, CA	1:200
Alexa Fluor donkey anti mouse 647	Life Technologies, Carlsbad, CA	1:200
Dapi	Sigma- Aldrich, Taufkirchen, Germany	1:1000

Table S4. Primer sequences and probes for qRT-PCR

Target genes	Forward primer (L):	Reverse primer (R):	Probe:
<b>Mouse:</b>			
<i>Ang4</i>	ccccagttggaggaaagc	cgtaggaattttcgtaccttca	106
<i>Atf5</i>	ttttatgaagaggaataagatgaggt	ggaggctgcaccaacaat	16
<i>Chop</i>	cgacagagccagaataacagc	aagggtagacggagccagt	91
<i>CoxIV</i>	tcactgcgctcgttctgat	cgatcgaaagtatgagggatg	7
<i>Defa5</i>	ttttgggacctgcagaaatc	tggttggtgaccatccttgtt	84
<i>Dll4</i>	agggtgccacttcggttacac	gggagagcaaatggctgata	106
<i>Grp78</i>	ctgaggcggtatttgggaaag	tcatgacattcagtcagcaa	105
<i>Hif1a</i>	gcactagacaaagttcacctgaga	cgctatccacatcaaagcaa	95
<i>Hprt</i>	tctcctcagaccgctttt	cctggtcatcatcgctaac	95
<i>Hsp10</i>	ggcccaggttcagagtcc	tgtcaaagagcggaagaaactt	77
<i>Hsp60</i>	tcttcaggttggtgcagta	cccctcttctccaaacactg	1
<i>Lc3a</i>	gaccagcaccacagtaagat	tgggaccagaaacttggtct	27
<i>Lgr5</i>	cttcactcgggtcagtgct	cagccagctaccaaatagggtg	60
<i>Lyz1</i>	ggcaaaaccccaagatctaa	tctctcaccaccctctttgc	46
<i>Olfm4</i>	gaaattcgagagagagtttctaagg	gacctctactcggaccgtca	92
<i>Otc</i>	gctgtcatggtatccctgct	tttcttttgacaggcatca	99
<i>Pdha</i>	catcgttgagctcaggtg	cgccgtataatgtcaaacagac	15
<i>Prkaa2</i>	cagagcaaagcgtgtgacat	ttctcttactcgaagatggatgc	41
<i>Trb3</i>	gtcgctttgtcttcagcaact	tcatctgatccagtcacacg	67
<i>Yy1</i>	ctggagaaaagcccttcag	gtcgaaggggcacacatag	94
<b>Human:</b>			
<i>CHOP</i>	Cagagctggaacctgaggag	tgtttatggctgcttgggtg	9
<i>DLL1</i>	gtggggagaaagtgtgcaa	tcacaaaatccatgctgctc	20
<i>HIF1A</i>	gaacctgatgctttaactttgct	tgctggatcatcagtttctgtg	28
<i>HPRT1</i>	tgatagatccattcctatgacttaga	caagacattctccagttaaagt	22
<i>LGR5</i>	accagactatgcctttggaac	tcccagggagtggtattctatt	78
<i>LYZ</i>	ccgctactgggtgaatgatgg	catcagcgatgttatcttgcag	68
<i>PLA2G2A</i>	aaatttctgagctacaagtttagcaac	ttatcacactcacacagttgacttct	32
<i>PRKAA1</i>	ctgatatttcatggtgatggaat	gacgccgactttcttttca	63

## References

- 1 Berger E, Rath E, Yuan D, Waldschmitt N, Khaloian S, Allgauer M, *et al.* Mitochondrial function controls intestinal epithelial stemness and proliferation. *Nat Commun* 2016;**7**:13171.
- 2 Harder U, Koletzko B, Peissner W. Quantification of 22 plasma amino acids combining derivatization and ion-pair LC-MS/MS. *J Chromatogr B Analyt Technol Biomed Life Sci* 2011;**879**:495-504.
- 3 Gucciardi A, Pirillo P, Di Gangi IM, Naturale M, Giordano G. A rapid UPLC-MS/MS method for simultaneous separation of 48 acylcarnitines in dried blood spots and plasma useful as a second-tier test for expanded newborn screening. *Anal Bioanal Chem* 2012;**404**:741-51.
- 4 Erben U, Loddenkemper C, Doerfel K, Spieckermann S, Haller D, Heimesaat MM, *et al.* A guide to histomorphological evaluation of intestinal inflammation in mouse models. *Int J Clin Exp Pathol* 2014;**7**:4557-76.
- 5 Auzolle C, Nancey S, Tran-Minh ML, Buisson A, Pariente B, Stefanescu C, *et al.* Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. *Aliment Pharmacol Ther* 2018;**48**:924-32.
- 6 Hammoudi N, Cazals-Hatem D, Auzolle C, Gardair C, Ngollo M, Bottois H, *et al.* Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease. *Clin Gastroenterol Hepatol* 2019.
- 7 Zietek T, Rath E. Chapter 3 - Intestinal organoids: Mini-guts grown in the laboratory. In: Davies JA, Lawrence ML, eds. *Organs and Organoids*: Academic Press, 2018:43-71.